Stadler J, Maartens G, Meintjes G, Wasserman S
Front Pharmacol. 2023; 14:1100488.
PMID: 36817137
PMC: 9932205.
DOI: 10.3389/fphar.2023.1100488.
Brunaugh A, Walz A, Warnken Z, Pearce C, Munoz Gutierrez J, Koleng J
Antimicrob Agents Chemother. 2022; 66(9):e0018622.
PMID: 35943265
PMC: 9487480.
DOI: 10.1128/aac.00186-22.
Park S, Jung J, Kim J, Han S, Ryoo S
J Clin Med. 2022; 11(7).
PMID: 35407536
PMC: 9000149.
DOI: 10.3390/jcm11071927.
Decroo T, Maug A, Hossain M, Uwizeye C, Gumusboga M, Demeulenaere T
PLoS One. 2020; 15(8):e0238016.
PMID: 32866193
PMC: 7458281.
DOI: 10.1371/journal.pone.0238016.
Bvumbi M
ChemMedChem. 2020; 15(23):2207-2219.
PMID: 32844566
PMC: 7756396.
DOI: 10.1002/cmdc.202000580.
Development of a Self-Emulsifying Drug Delivery System for Optimized Topical Delivery of Clofazimine.
van Staden D, Du Plessis J, Viljoen J
Pharmaceutics. 2020; 12(6).
PMID: 32521671
PMC: 7356627.
DOI: 10.3390/pharmaceutics12060523.
Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report.
Erber J, Weidlich S, Tschaikowsky T, Rothe K, Schmid R, Schneider J
BMC Infect Dis. 2020; 20(1):365.
PMID: 32448204
PMC: 7245858.
DOI: 10.1186/s12879-020-05075-7.
and Activities of the Riminophenazine TBI-166 against .
Xu J, Wang B, Fu L, Zhu H, Guo S, Huang H
Antimicrob Agents Chemother. 2019; 63(5).
PMID: 30782992
PMC: 6496038.
DOI: 10.1128/AAC.02155-18.
Formulation of Natural Oil Nano-Emulsions for the Topical Delivery of Clofazimine, Artemisone and Decoquinate.
Burger C, Aucamp M, du Preez J, Haynes R, Ngwane A, Du Plessis J
Pharm Res. 2018; 35(10):186.
PMID: 30088097
DOI: 10.1007/s11095-018-2471-9.
Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
Cavanaugh J, Jou R, Wu M, Dalton T, Kurbatova E, Ershova J
J Antimicrob Chemother. 2017; 72(6):1678-1687.
PMID: 28333192
PMC: 5890777.
DOI: 10.1093/jac/dkx022.
New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid.
Brigden G, Hewison C, Varaine F
Infect Drug Resist. 2015; 8:367-78.
PMID: 26586956
PMC: 4634826.
DOI: 10.2147/IDR.S68351.
Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas.
Irwin S, Gruppo V, Brooks E, Gilliland J, Scherman M, Reichlen M
Antimicrob Agents Chemother. 2014; 58(7):4026-34.
PMID: 24798275
PMC: 4068578.
DOI: 10.1128/AAC.02565-14.
Determination of the activity of standard anti-tuberculosis drugs against intramacrophage Mycobacterium tuberculosis, in vitro: MGIT 960 as a viable alternative for BACTEC 460.
Jhamb S, Goyal A, Singh P
Braz J Infect Dis. 2014; 18(3):336-40.
PMID: 24709416
PMC: 9427504.
DOI: 10.1016/j.bjid.2013.12.004.
Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies.
Hwang T, Dotsenko S, Jafarov A, Weyer K, Falzon D, Lunte K
BMJ Open. 2014; 4(1):e004143.
PMID: 24384902
PMC: 3902362.
DOI: 10.1136/bmjopen-2013-004143.
Rising to the challenge: new therapies for tuberculosis.
Wong E, Cohen K, Bishai W
Trends Microbiol. 2013; 21(9):493-501.
PMID: 23764389
PMC: 4237170.
DOI: 10.1016/j.tim.2013.05.002.
Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.
Gopal M, Padayatchi N, Metcalfe J, ODonnell M
Int J Tuberc Lung Dis. 2013; 17(8):1001-7.
PMID: 23541151
PMC: 4003893.
DOI: 10.5588/ijtld.12.0144.
World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?.
Dooley K, Obuku E, Durakovic N, Belitsky V, Mitnick C, Nuermberger E
J Infect Dis. 2012; 207(9):1352-8.
PMID: 22807518
PMC: 3693592.
DOI: 10.1093/infdis/jis460.
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.
Tasneen R, Li S, Peloquin C, Taylor D, Williams K, Andries K
Antimicrob Agents Chemother. 2011; 55(12):5485-92.
PMID: 21930883
PMC: 3232786.
DOI: 10.1128/AAC.05293-11.
Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation.
Lu Y, Zheng M, Wang B, Fu L, Zhao W, Li P
Antimicrob Agents Chemother. 2011; 55(11):5185-93.
PMID: 21844321
PMC: 3195009.
DOI: 10.1128/AAC.00699-11.
Drug-resistant tuberculosis: what are the treatment options?.
Albanna A, Menzies D
Drugs. 2011; 71(7):815-25.
PMID: 21568360
DOI: 10.2165/11585440-000000000-00000.